Medical treatment of DLK1 associated diseases by control of the natural antisense transcript to delta Mr. 1 homolog (DLK1)

Title:

Medical treatment of DLK1 associated diseases by control of the natural antisense transcript to delta Mr. 1 homolog (DLK1)

Document Type and Number:

Japanese Patent JP5904935

Kind Code:

B2

Abstract:

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like 1 homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like 1 homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLK1.

Inventors:

Joseph Colored
Olga Corkova Sherman
Carlos Coit

Application Number:

JP2012500869A

Publication Date:

April 20, 2016

Filing Date:

March 16, 2010

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Kuruna Incorporated

International Classes:

C12N15/113; A61K31/7088; A61K31/712; A61K31/7125; A61K48/00

Foreign References:

US20080293142

Other References:

PLoS Genet.,2009,5(2),e1000392
J.Cell Sci.,2008,121(Pt22),p.3815-23
Exp.Neurol.,2007,204(2),p.791-801
Science,2005,309(5740),p.1564-6

Attorney, Agent or Firm:

Yasuhiko Murayama
Shinya Mitsuhiro
Tatsuhiko Abe

Previous Patent: A system for the tile writing magnetism record in disk driving, a method, and a device

Next Patent: Hydrogel in which pouring for supplementing the skin with glycerol over a long period of time is pos...